• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH
Click for more information
25.0% 0.3¢

ALTERITY THERAPEUTICS LIMITED - News & Media

Market Cap $15.96M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results for Alterity.

17 Jul 2024 11:45 (AEST)

Alterity Therapeutics (ASX:ATH) doses first European patient in phase two MSA trial

Alterity Therapeutics (ASX:ATH) has dosed its first patient in Italy as part of its phase two clinical trial in multiple system atrophy (MSA).

08 Mar 2023 09:19 (AEDT)



(20min delay)
Last
0.3¢ 		Change
-0.001(25.0%) 		Mkt cap ! $15.96M
Open High Low Value Volume
0.4¢ 0.4¢ 0.3¢ $32.63K 10.83M

Buyers (Bids)

No. Vol. Price($)
28 21801548 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 130971725 28
View Market Depth
Last trade - 16.10pm 03/10/2024 (20 minute delay) ?
Last
0.3¢ 		  Change
-0.001 ( 0.00 %)
Open High Low Volume
0.3¢ 0.4¢ 0.3¢ 16250578
Last updated 14.49pm 03/10/2024 ?
ATH (ASX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Firefly positioned for copper growth in Canada ahead of resource update Firefly Metals Ltd has reported drilling reports from its Green Bay copper-gold project in Newfoundland, ahead of a resource update
Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20% Chariot has unveiled its vision for its US-based Black Mountain – aiming to fast-track its path to production by establishing a "pilot mine."
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.